Drug intelligence / Profile preview

LivPhcD

Development stage: Unknown
Lead developer: TCM Biotech
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

LivPhcD is a natural botanical dietary supplement developed by TCM Biotech, derived from *Cordyceps sinensis* mycelium. It has received US FDA New Dietary Ingredient (NDI) status, distinguishing it as a regulated supplement rather than a pharmaceutical drug. The product is specifically indicated for the support of liver health, targeting conditions such as nonalcoholic fatty liver disease (NAFLD), alcoholic fatty liver disease, and liver fibrosis. As a fungal mycelium extract, it leverages the bioactive compounds inherent in *Cordyceps* to provide hepatoprotective effects and support metabolic liver function.

Brand names: LivPhcD
Other names: Cordyceps sinensis mycelium

Beyond the preview

Go deeper on LivPhcD.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LivPhcD.

Explore the full profile